三孚股份(603938.SH):硅烷偶聯劑一期項目已產出合格產品
格隆匯12月15日丨三孚股份(603938.SH)披露“年產15000噸硅烷偶聯劑中間體項目”及“年產73000噸硅烷偶聯劑系列產品項目”實施進展,硅烷偶聯劑一期項目於2021年10月12日正式投料試車,所有工藝流程均已實現正常運轉。該項目產品未來主要作為硅烷偶聯劑二期項目的生產原料,近日,項目已產出合格產品,經自測產品已滿足自用需求,且部分品種已外售並經客户使用合格。
硅烷偶聯劑二期項目目前主體工程已建設完畢、主要設備已經安裝完畢,公司目前正在進行試車前期準備工作,並積極籌備各項試生產審批手續。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.